Abbott pairs generics with tax benefit

Share this article:

Abbott and Mylan are going into business together. Abbott announced Monday that it was selling its branded generics business to Mylan, with two things to note: Mylan's rights are limited to developed markets—Europe, Japan, Canada, Australia and New Zealand—and the drugs flowing away from Abbott and towards Mylan will be housed in a brand-new publicly traded company.

The deal is the latest of a host of the pharmaceutical industry's tax-oriented strategies. Bloomberg notes that the new business will be headquartered in the Netherlands, which will drop Abbott's tax rate to less than 21% at the beginning and which will continue to fall.

Abbott says the businesses being handed to Mylan in the all-stock deal garnered around $2 billion in 2013 sales and that the branded generics it's hanging on to earned around $2.9 billion in sales last year.

Abbott and Mylan expect the deal will close in the first quarter of 2015. Abbott noted in its announcement that it doesn't expect to hang onto its Mylan shares for the long haul “and plans ultimately to redeploy the net proceeds from this transaction to opportunities that would be accretive to earnings over time.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.